Morepen Laboratories Limited — Updates, 13-05-2025: Press Release (Revised)

Morepen Laboratories has announced a board meeting on the financial results for the quarter and half-year. FY25 PAT hit a record ₹118 crore, up 17%, with revenue at ₹1,830 crore (+7.4%) and EBITDA ₹192 crore (+11.5%). A proposed dividend of ₹0.20 per share marks a return after 23 years. The API segment led with ₹989 crore, boosted by exports to 80+ countries, while Medical Devices grew 12% to ₹496 crore on new products and capacity expansions. Solid operational momentum highlights growth across key verticals.